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Adam Timmis, Harry Hemingway
Summary
Background The contemporary associations of type 2 diabetes with a wide range of incident cardiovascular diseases 
have not been compared. We aimed to study associations between type 2 diabetes and 12 initial manifestations of 
cardiovascular disease.
Methods We used linked primary care, hospital admission, disease registry, and death certiﬁ cate records from the 
CALIBER programme, which links data for people in England recorded in four electronic health data sources. We 
included people who were (or turned) 30 years or older between Jan 1, 1998, to March 25, 2010, who were free from 
cardiovascular disease at baseline. The primary endpoint was the ﬁ rst record of one of 12 cardiovascular presentations in 
any of the data sources. We compared cumulative incidence curves for the initial presentation of cardiovascular disease 
and used Cox models to estimate cause-speciﬁ c hazard ratios (HRs). This study is registered at ClinicalTrials.gov 
(NCT01804439).
Findings Our cohort consisted of 1 921 260 individuals, of whom 1 887 062 (98·2%) did not have diabetes and 34 198 
(1·8%) had type 2 diabetes. We observed 113 638 ﬁ rst presentations of cardiovascular disease during a median follow-
up of 5·5 years (IQR 2·1–10·1). Of people with type 2 diabetes, 6137 (17·9%) had a ﬁ rst cardiovascular presentation, 
the most common of which were peripheral arterial disease (reported in 992 [16·2%] of 6137 patients) and heart 
failure (866 [14·1%] of 6137 patients). Type 2 diabetes was positively associated with peripheral arterial disease 
(adjusted HR 2·98 [95% CI 2·76–3·22]), ischaemic stroke (1·72 [1·52–1·95]), stable angina (1·62 [1·49–1·77]), heart 
failure (1·56 [1·45–1·69]), and non-fatal myocardial infarction (1·54 [1·42–1·67]), but was inversely associated with 
abdominal aortic aneurysm (0·46 [0·35–0·59]) and subarachnoid haemorrhage (0·48 [0·26–0.89]), and not associated 
with arrhythmia or sudden cardiac death (0·95 [0·76–1·19]).
Interpretation Heart failure and peripheral arterial disease are the most common initial manifestations of 
cardiovascular disease in type 2 diabetes. The diﬀ erences between relative risks of diﬀ erent cardiovascular diseases in 
patients with type 2 diabetes have implications for clinical risk assessment and trial design.
Funding Wellcome Trust, National Institute for Health Research, and Medical Research Council.
Copyright © Shah et al. Open Access article distributed under the terms of CC BY.
Introduction
Patients with type 2 diabetes are at increased risk of 
cardiovascular diseases and associated clinical 
complications.1 Although type 2 diabetes has become an 
increasingly common disease, estimated to aﬀ ect 
380 million people worldwide by 2025,2 the incidence of 
myocardial infarction and stroke has declined rapidly 
during the past few decades. However, myocardial 
infarction and stroke continue to be chosen as primary 
outcomes of major type 2 diabetes trials (appendix).3 To 
reliably estimate the beneﬁ t of type 2 diabetes prevention 
and treatment in trials, or the future burden of type 2 
diabetes-associated diseases for health-care planning, a 
better understanding of how type 2 diabetes aﬀ ects the 
risk of other acute and chronic cardiovascular 
manifestations is needed.
Previous studies have not compared the relation 
between type 2 diabetes and a wide range of 
cardiovascular outcomes such as heart failure, peripheral 
arterial disease, abdominal aortic aneurysm, and 
ventricular arrhythmias in the same study, but have 
instead focused on a narrower range of disease 
outcomes, usually just one or two.4 Such comparisons 
need large study samples to reliably estimate associations 
for rare outcomes. Since early reports were published,5 
results of several small studies have shown that the 
eﬀ ect of type 2 diabetes on cardiovascular manifestations 
diﬀ ers according to the speciﬁ c cardiovascular outcome 
measured6 and the sex of the participant.7 However, 
these studies were not designed to reliably assess 
associations with several cardiovascular diseases or 
across population subgroups.
We have addressed these gaps in knowledge by 
establishing a large prospective cohort using linked 
electronic health records,8,9 which combine information 
about diabetes diagnosis, risk factors, and medication use 
with future cardiovascular events. Our objective was to 
investigate and compare associations between type 2 
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diabetes and future risk of 12 of the most common initial 
cardiovascular presentations in men and women.
Methods
Study population
The study population was drawn from the CALIBER 
programme (CArdiovascular disease research using 
LInked Bespoke studies and Electronic health Records),9 
which links four sources of electronic health data in 
England: primary care health records (coded diagnoses, 
clinical measurements, and prescriptions) from general 
practices contributing to the Clinical Practice Research 
Datalink (CPRD), coded hospital discharges (hospital 
episode statistics), the Myocardial Ischaemia National 
Audit Project (MINAP), and death registrations. 
Individuals were eligible for inclusion if they were (or 
turned) 30 years or older between Jan 1, 1998, and March 
25, 2010, and if they had been registered for at least 1 year 
in a practice that met research data recording standards. 
We excluded individuals with a history of cardiovascular 
disease or if they had a record of pregnancy within 
6 months of study entry (appendix).
Approval was granted by the independent scientiﬁ c 
advisory committee of the Medicines and Healthcare 
products Regulatory Agency (protocol 12_117) and the 
MINAP Academic Group.
Procedures
We deﬁ ned individuals as having diabetes at baseline 
(type 1, type 2, or uncertain type) on the basis of coded 
diagnoses recorded in CPRD or hospital episode statistics 
at or before study entry (appendix). Participants who 
developed new-onset diabetes during follow-up were 
analysed according to their baseline status of no diabetes. 
We compared people with type 2 diabetes to those without 
diabetes; we excluded people with type 1 diabetes or 
diabetes of uncertain type. In each participant with diabetes, 
we assessed glycaemic control by taking the mean of all the 
HbA1c measurements from 3 years before study entry to 
3 years after, ignoring values occurring after an endpoint.
For continuous variables (BMI, HDL cholesterol, total 
cholesterol, and systolic blood pressure) we used, as a 
baseline value, the most recent measurement recorded in 
CPRD in the year before study entry, but included 
measurements outside this time window in imputation 
models. Social deprivation was included in models as 
quintiles of the index of multiple deprivation,10 a score 
calculated for each participant’s neighbourhood on the 
basis of social indices such as income, education, and 
employment. Data recorded before study entry were used 
to classify participants as never smokers, ex-smokers, or 
current smokers at baseline.
Outcomes
The primary endpoint was the ﬁ rst record of one of the 
following 12 cardiovascular presentations in any of the 
data sources: stable angina, unstable angina, myocardial 
infarction, unheralded coronary death, heart failure, 
transient ischaemic attack, ischaemic stroke, sub-
arachnoid haemorrhage, intracerebral haemorrhage, 
peripheral arterial disease, abdominal aortic aneurysm, 
and a composite outcome classiﬁ ed as arrhythmia or 
sudden cardiac death, which consisted of cardioversion, 
ventricular arrhythmia, implantable cardioverter 
deﬁ brillator, cardiac arrest, or sudden cardiac death. 
Any events occurring after the ﬁ rst cardiovascular 
presentation were ignored. Endpoint deﬁ nitions are 
described in the appendix and coding algorithms are 
available on the CALIBER portal. Secondary outcomes 
were cardiovascular mortality and all-cause mortality.
Statistical analysis
We plotted crude cumulative incidence curves for each 
cardiovascular endpoint for people with no diabetes and 
those with type 2 diabetes, using age as the timescale 
(appendix). Follow-up was censored at the occurrence of 
a primary endpoint, death, de-registration from the 
practice, or the last data collection for the practice, 
whichever occurred ﬁ rst.
We used multivariable Cox regression to calculate 
cause-speciﬁ c hazards for associations between type 2 
diabetes and initial presentations of cardiovascular 
disease. The proportional hazards assumption was 
veriﬁ ed by plotting Schoenfeld residuals (appendix). In 
the primary analysis, we compared individuals with 
type 2 diabetes to those without diabetes, adjusting for 
age, sex, BMI, deprivation, HDL cholesterol, total 
cholesterol, systolic blood pressure, smoking status, and 
prescription of statins or other antihypertensive 
medication in the year before study entry. The baseline 
hazard function of each model was stratiﬁ ed by general 
practice and sex, and we used multiple imputation to 
account for missing covariate data (appendix). We also 
did analyses adjusted for age and sex only, and analyses 
adjusted for age, sex, and cardiovascular risk factors. We 
assessed interactions with age and sex. In patients with 
type 2 diabetes, we estimated hazard ratios (HRs) by level 
of glycaemic control (HbA1c concentration). We grouped 
patients with type 2 diabetes into categories by HbA1c 
concentration, with cutoﬀ  points at 48 mmol/mol (6·5%, 
the threshold for diagnosis of diabetes),11 and 
58 mmol/mol (7·5%, the recommended threshold for 
initiation of thiazolidinedione or insulin in type 2 
diabetes in UK guidelines).12
15% of people with diabetes did not have a code for 
the type of diabetes (appendix) and were excluded from 
the primary analyses. To assess the eﬀ ect of this 
potential misclassiﬁ cation bias, we did a sensitivity 
analysis comparing individuals with any diabetes 
diagnosis to those without diabetes (most patients with 
diabetes in a cohort of this age would have type 2 
diabetes). We did sensitivity analyses ignoring endpoints 
recorded only in primary care (CPRD), restricted to fatal 
endpoints, or restricted to individuals who entered the 
For the CALIBER portal see 
http://www.caliberresearch.org/
portal/
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Women Men
No diabetes 
(n=955 655)
Type 2 diabetes 
(n=15 805)
No diabetes 
(n=931 407)
Type 2 diabetes 
(n=18 393)
Age, years 48·2 (16·2) 64·7 (14·4) 45·4 (14) 60·8 (13)
Social deprivation* 184 942 (19·4%) 4313 (27·3%) 189 247 (20·3%) 4285 (23·3%)
Ethnic origin
White 503 274 (90·8%) 9641 (81·8%) 388 763 (90·5%) 10 716 (82·4%)
South Asian 14 673 (2·6%) 912 (7·7%) 12 865 (3·0%) 1041 (8·0%)
Black 16 722 (3·0%) 748 (6·3%) 13 148 (3·1%) 670 (5·2%)
Other 19 328 (3·5%) 491 (4·2%) 14 640 (3·4%) 579 (4·5%)
Smoking status
Current smoker 130 946 (17·6%) 2028 (14·4%) 148 020 (23·7%) 3327 (20·6%)
Ex-smoker 108 593 (11·4%) 2927 (18·5%) 109 538 (11·8%) 5507 (29·9%)
Never smoked 506 383 (67·9%) 9158 (64·9%) 366 729 (58·7%) 7327 (45·3%)
Systolic blood pressure†, mm Hg 127 (19·6) 141 (19·7) 133 (17·2) 139 (17·6)
Diastolic blood pressure†, mm Hg 77·1 (10·3) 79·5 (10·1) 80·3 (10·0) 80·5 (10·0)
Total cholesterol†, mmol/L 5·54 (1·14) 5·08 (1·22) 5·39 (1·11) 4·77 (1·16)
HDL cholesterol†, mmol/L 1·57 (0·45) 1·34 (0·39) 1·28 (0·37) 1·14 (0·33)
BMI†, kg/m² 26·0 (5·59) 30·5 (6·76) 26·5 (4·43) 29·3 (5·43)
Random glucose concentration†, mmol/L 5·35 (1·16) 10·4 (4·93) 5·56 (1·29) 10·7 (4·78)
Fasting glucose concentration†, mmol/L 5·14 (0·75) 8·72 (3·53) 5·31 (0·79) 9·1 (3·51)
Glycaemic control‡
HbA1c recorded 12 835 (1·3%) 12 187 (77·1%) 12 031 (1·3%) 14 435 (78·5%)
HbA1c, mmol/mol 44·3 (14·7) 59·3 (18·0) 46·9 (16·3) 60·5 (18·1)
HbA1c <48 mmol/mol (6·5%) 9468 (73·8%) 3445 (28·3%) 8030 (66·7%) 3671 (25·4%)
HbA1c 48–58 mmol/mol (6·5–7·5%) 1854 (14·4%) 3458 (28·4%) 2004 (16·7%) 4075 (28·2%)
HbA1c ≥58 mmol/mol (7.5%) 1513 (11·8%) 5284 (43·4%) 1997 (16·6%) 6689 (46·3%)
Diabetes treatment in year before study entry
Diet only NA 4591 (29·0%) NA 5467 (29·7%)
Metformin 884 (0·1%) 7714 (48·8%) 106 (<0·1%) 8764 (47·6%)
Sulfonylurea 133 (<0·1%) 6241 (39·5%) 124 (<0·1%) 7526 (40·9%)
Insulin 189 (<0·1%) 1939 (12·3%) 77 (<0·1%) 1882 (10·2%)
Thiazolidinedione 5 (<0·1%) 962 (6·1%) 6 (<0·1%) 1225 (6·7%)
DPP-4 inhibitor, meglitinide derivative, or GLP-1 receptor 
agonist
1 (<0·1%) 153 (1·0%) 1 (<0·1%) 182 (1·0%)
Cardiovascular preventive treatment in year before study entry
Statin 18 233 (1·9%) 5636 (35·7%) 19 537 (2·1%) 6680 (36·3%)
Any antihypertensive medication 156 098 (16·3%) 9404 (59·5%) 99 179 (10·6%) 9898 (53·8%)
ACE inhibitor 59 412 (6·2%) 5278 (33·4%) 44 176 (4·7%) 6333 (34·4%)
Angiotensin receptor blocker 7324 (0·8%) 1357 (8·6%) 5276 (0·6%) 1263 (6·9%)
β blocker 54 861 (5·7%) 2755 (17·4%) 34 455 (3·7%) 2730 (14·8%)
Subset of patients entering the study from 2004 onwards
Number of patients 283 993 6900 293 890 8 212
Age, years 43·6 (15·6) 64·1 (15·7) 41·4 (13·0) 59·6 (13·7)
HbA1c recorded‡ 6191 (2·2%) 6509 (94·3%) 5677 (1·9%) 7816 (95·2%)
Statin prescription in year before study entry 11 774 (4·1%) 4383 (63·5%) 13 059 (4·4%) 5395 (65·7%)
Antihypertensive prescription in year before study entry 43 736 (15·4%) 4663 (67·6%) 33 535 (11·4%) 5464 (66·5%)
ACE inhibitor prescription in year before study entry 20 577 (7·2%) 2866 (41·5%) 17 531 (6·0%) 3776 (46·0%)
Data are mean (SD) or number (%). Proportion of participants with non-missing values of covariates: ethnic origin 52·5% (1 002 211 of 1 921 260 participants), smoking 
72·9% (1 400 483 participants), systolic blood pressure 42·2% (811 591 participants), diastolic blood pressure 42·2% (811 591 participants), total cholesterol 8·3% 
(158 990 participants), HDL cholesterol 5·4% (103 809 participants), and BMI 30·3% (582 172 participants) . NA=not applicable. ACE=angiotensin-converting enzyme. 
*Number (%) in most deprived quintile. †Most recent measurement within 1 year of study entry. ‡Mean HbA1c during the 3 years before or after study entry.
Table: Baseline characteristics of 1 921 260 people without cardiovascular diseases at baseline, according to sex and type 2 diabetes status
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study after 2004 (when recording of covariates would be 
expected to be more complete after introduction of the 
Quality and Outcomes Framework to incentivise good 
performance in the care of speciﬁ ed diseases).13 We did 
analyses using R 2.15.
This trial is registered with ClinicalTrials.gov, number 
NCT01804439.
Role of the funding source
The funder of the study had no role in the conduct of the 
study or study design, in the collection, analysis, or inter-
pretation of the data, or in the writing of this report. 
ADS, SD, and ER had access to the raw data for this 
study. The corresponding author had full access to all of 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
The study cohort included 1 921 260 individuals, of whom 
1 887 062 (98·2%) did not have diabetes and 34 198 (1·2%) 
had type 2 diabetes. People with type 2 diabetes had 
lower mean HDL cholesterol and higher mean BMI than 
people without diabetes (table). The use of statins and 
antihypertensive medication was greater in people with 
type 2 diabetes than in those without diabetes, and 
increased over time (table). People with type 2 diabetes 
were about twice as likely to be black or south Asian as 
those without diabetes (table).
The prevalence of any type of diabetes in all individuals 
in CALIBER aged 40–50 years (with or without previous 
cardiovascular disease) was 1·52% (95% CI 1·47–1·57) in 
women and 2·25% (2·19–2·32) in men (appendix). 
During follow-up, 51 690 participants were newly 
diagnosed with diabetes, with a median time to diagnosis 
from study entry of 4·9 years (IQR 2·4–7·7).
We analysed 113 638 cardiovascular events over 
11·6 million person-years of follow-up (median follow-up 
5·5 years [IQR 2·1–10·1]). Of these events, 6137 (5·4%) 
were in people with type 2 diabetes, who accrued 
162 756 person-years of follow-up. Peripheral arterial 
disease was the ﬁ rst presentation in 992 (16·2%) of the 
6137 patients with type 2 diabetes who had cardiovascular 
events, and heart failure was the ﬁ rst presentation in 
866 (14·1%) of these patients (ﬁ gure 1). By contrast, 
10 074 (9·4%) of 107 501 people without diabetes 
presenting with cardiovascular events had peripheral 
arterial disease, and 13 072 (12·2%) had heart failure 
(appendix). Cumulative incidence curves show substantial 
diﬀ erences in the direction and strength of the 
associations between each of the cardiovascular 
manifestations and type 2 diabetes (ﬁ gure 2; appendix). 
The diﬀ erence in the cumulative incidence of peripheral 
arterial disease between people with and without diabetes 
was the largest of all the cardiovascular diseases; a woman 
with type 2 diabetes at age 40 years had a 9·7% risk 
(95% CI 8·4–11·1) of developing peripheral arterial 
disease as her ﬁ rst presentation of cardiovascular disease 
by age 80 years; a woman without diabetes had a 3·2% 
risk (3·1–3·3). The corresponding ﬁ gures for men were 
11·7% (10·5–13·0) and 4·5% (4·4–4·7).
In multivariable Cox models, we noted strong positive 
associations between type 2 diabetes and peripheral 
arterial disease, ischaemic stroke, stable angina, heart 
failure, and non-fatal myocardial infarction (ﬁ gure 3; 
appendix).
By contrast, type 2 diabetes was inversely associated 
with abdominal aortic aneurysm and subarachnoid 
haemorrhage (ﬁ gure 3). No statistically signiﬁ cant 
association between arrhythmia or sudden cardiac death 
and type 2 diabetes was noted (ﬁ gure 3). The strengths of 
associations were slightly attenuated by adjustment for 
risk factors and medication compared with the model 
adjusted for age and sex only (appendix).
For individuals aged 40 years without cardiovascular 
disease, the overall estimated risk of developing any 
cardiovascular disease by age 80 years was 30·7% 
(95% CI 30·3–31·0) for women without diabetes and 
44·3% (43·8–44·7) for men without diabetes, compared 
with 58·2% (54·9–61·4) for women with type 2 diabetes 
and 67·4% (64·4–70·4) for men with type 2 diabetes 
(appendix). We observed a slightly greater risk of non-
fatal myocardial infarction associated with type 2 diabetes 
in women younger than 60 years than in men younger 
than 60 years, but noted no other statistically signiﬁ cant 
diﬀ erences between sexes (ﬁ gure 4). Associations 
between type 2 diabetes and coronary endpoints, 
transient ischaemic attack, ischaemic stroke, and 
peripheral arterial disease were signiﬁ cantly stronger in 
younger age groups than in older age groups (appendix). 
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Figure 1: Distribution of initial presentations of cardiovascular diseases
Distribution of initial presentations of cardiovascular disease in participants with 
and without type 2 diabetes and no history of cardiovascular disease.
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HRs for type 2 diabetes and cardiovascular endpoints 
were consistent across ethnic groups for the common 
endpoints such as heart failure, stable angina, and 
peripheral arterial disease, but the results for less 
common endpoints were imprecise because of the small 
number of events (data not shown).
In individuals with type 2 diabetes, the risk of 
cardiovascular diseases associated with the presence of 
type 2 diabetes was highest for those with an HbA1c 
concentration of 58 mmol/mol (7·5%) or higher or those 
in whom HbA1c had not been recorded (appendix). 
Individuals with type 2 diabetes and an HbA1c 
concentration of less than 48 mmol/mol (6·5%) had an 
increased risk of peripheral arterial disease (HR 1·82, 
95% CI 1·52–2·18) and ischaemic stroke (1·53, 
1·18–1·98), but no greater risk of any of the other 
cardiovascular diseases (appendix).
Overall, results were robust to a range of modiﬁ cations 
explored in our sensitivity analyses, including a 
comparison of people with any diabetes versus no diabetes 
(appendix). Results did not diﬀ er when primary care data 
were omitted as a source of endpoint information, apart 
from a slightly stronger association between type 2 
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Figure 2: Cumulative incidence curves for the incidence of ﬁ rst presentation of 12 cardiovascular diseases in patients aged ≥40 years, by diabetes status
The curves begin at age 40 years rather than 30 years because 40 years is a typical age for a patient to develop type 2 diabetes. 
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Figure 3: Association of type 2 diabetes with 12 cardiovascular diseases in patients aged ≥30 years
Adjusted hazard ratios (HRs) for diﬀ erent initial presentations of cardiovascular diseases associated with type 2 
diabetes, adjusted for age, sex, BMI, deprivation, HDL cholesterol, total cholesterol, systolic blood pressure, smoking 
status, and statin and antihypertensive drug prescriptions. Two non-speciﬁ c components of the primary endpoint 
are not shown in the ﬁ gure for simplicity (they are inprecisely recorded versions of one of the 12 initial 
presentations): coronary disease not further speciﬁ ed, HR 1·58 (95% CI 1·45–1·73), p<0·0001; stroke not further 
speciﬁ ed 1·64 (1·48–1·81), p<0·0001.
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diabetes and heart failure (HR 2·15 [95% CI 1·96–2·36] 
when primary care data were omitted vs 1·56 [1·45–1·69] 
when included; appendix). Type 2 diabetes was strongly 
associated with composite cardiovascular mortality and 
all-cause mortality (appendix).
Discussion
This population-based, contemporary study of nearly 
2 million individuals with a median follow-up of 
5·5 years provides strong evidence that associations 
between type 2 diabetes and 12 speciﬁ c cardiovascular 
disease outcomes diﬀ er in terms of direction and 
magnitude of eﬀ ects. Our ﬁ ndings draw attention to the 
high absolute and relative risks of incident peripheral 
arterial disease, heart failure, and stable angina in people 
with type 2 diabetes,1,11 diseases that diﬀ er in preventive 
strategies and that often are poorly represented in the 
primary endpoint of randomised trials.
Peripheral arterial disease is one of the most common 
ﬁ rst presentations of cardiovascular disease, consistent 
with the increase in prevalence between 2000 and 2010 
reported in a systematic review.14 Furthermore, of the 
12 diseases studied, peripheral arterial disease showed 
the strongest association with type 2 diabetes, with an 
adjusted HR of 2·98 (95% CI 2·76–3·22), consistent 
with previous studies.14 Heart failure was also one of the 
Figure 4: Hazard ratios for association of type 2 diabetes with 12 cardiovascular diseases by sex and age
Hazard ratios by sex and age group for the association of diﬀ erent initial presentations of cardiovascular disease with type 2 diabetes, adjusted for age, BMI, 
deprivation, HDL cholesterol, total cholesterol, systolic blood pressure, smoking status, and statin and antihypertensive drug prescriptions. NA=not applicable.
Initial presentation of cardiovascular disease
Stable angina
Women  
Men
Unstable angina  
Women  
Men
Non-fatal myocardial infarction  
Women  
Men
Unheralded coronary death  
Women  
Men
Heart failure  
Women  
Men
Arrhythmia or sudden cardiac death  
Women  
Men
Transient ischaemic attack  
Women  
Men
Ischaemic stroke  
Women  
Men
Subarachnoid haemorrhage  
Women  
Men
Intracerebral haemorrhage  
Women  
Men
Peripheral arterial disease  
Women  
Men
Abdominal aortic aneurysm  
Women  
Men
Age <60 years
0·25 0·5 1 2 4 8
Hazard ratio
Hazard ratio
(95% CI)
2·50 (2·00−3·11)
1·79 (1·49−2·16)
2·13 (1·54−2·94)
1·88 (1·45−2·45)
2·68 (2·03−3·54)
1·71 (1·45−2·00)
2·40 (1·28−4·52)
1·59 (1·10−2·28)
3·37 (2·41−4·73)
2·32 (1·79−3·01)
0·76 (0·31−1·86)
1·82 (1·24−2·66)
1·69 (1·16−2·47)
1·75 (1·32−2·33)
3·05 (1·92−4·85)
2·39 (1·69−3·38)
0·48 (0·12−1·97)
··
1·13 (0·41−3·08)
2·20 (1·26−3·84)
5·11 (4·05−6·44)
3·77 (3·21−4·44)
··
0·49 (0·18−1·32)
pinteraction value Hazard ratio
(95% CI)
pinteraction value
0·017
0·54
0·0048
0·25
0·076
0·073
0·88
0·39
NA
0·25
0·028
NA
Age ≥60 years
0·25 0·5 1 2 4 8
Hazard ratio
1·51 (1·31−1·74)
1·70 (1·50−1·93)
1·35 (1·05−1·74)
1·30 (1·00−1·68)
1·61 (1·40−1·86)
1·34 (1·17−1·52)
1·46 (1·17−1·83)
1·32 (1·08−1·62)
1·50 (1·35−1·67)
1·43 (1·28−1·60)
0·85 (0·56−1·30)
0·73 (0·52−1·01)
1·45 (1·26−1·67)
1·36 (1·17−1·58)
1·63 (1·36−1·96)
1·56 (1·29−1·90)
0·67 (0·29−1·53)
0·56 (0·18−1·78)
1·05 (0·72−1·54)
1·30 (0·92−1·83)
2·77 (2·44−3·13)
2·60 (2·32−2·92)
0·45 (0·27−0·76)
0·47 (0·34−0·64)
0·18
0·82
0·051
0·5
0·54
0·55
0·51
0·75
0·81
0·41
0·45
0·9
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most common ﬁ rst presentations (accounting for 14·4% 
of events in people with type 2 diabetes). Our deﬁ nition 
excludes heart failure occurring after acute myocardial 
infarction, but we have to interpret this result with 
caution because we know that our data sources miss 
some cases of myocardial infarction.15 Possible 
mechanisms might include long-term hypertension, 
chronic hyperglycaemia, microvascular disease, 
glycosylation of myocardial proteins, diabetic 
nephropathy, and autonomic neuropathy.1 Similar to the 
meta-analysis of cohort studies in the Emerging Risk 
Factors Collaboration,4 we noted a weaker association of 
cardiovascular disease with type 2 diabetes in people 
60 years or older than in younger people.
A novel ﬁ nding was the association of type 2 diabetes 
with reduced incidence of two major aneurysmal 
diseases: abdominal aortic aneurysm and subarachnoid 
haemorrrhage. An inverse association between diabetes 
and abdominal aortic aneurysm has been suggested by 
cross-sectional studies of abdominal aortic aneurysm 
screening and case-control studies,6,16,17 but evidence from 
large prospective cohort studies has been mixed.18,19 With 
3113 abdominal aortic aneurysm events, our study is one 
of the largest cohort studies investigating this outcome,18,19 
and makes a substantial contribution to the evidence for 
a possible causal relation.
No previous cohort study has been large enough to 
investigate the association of type 2 diabetes with 
subarachnoid haemorrhage, but several case-control 
studies are consistent with our results (panel).20 These 
ﬁ ndings support the need to identify potential 
mechanisms that might have therapeutic implications. 
Such mechanisms might include diabetes-mediated 
changes in the vascular extracellular matrix, such as 
glycation of the extracellular matrix and covalent cross-
linking between elastin and collagen in the aortic wall.21
Several studies have shown that type 2 diabetes is 
associated with out-of-hospital cardiac arrest and sudden 
cardiac death,22,23 and an important unanswered question 
has been the extent to which this eﬀ ect is mediated by 
incident diseases known to increase arrhythmic risk 
such as myocardial infarction and heart failure. In this 
study we looked at the initial presentation of 
cardiovascular disease—ie, arrhythmia with no previous 
myocardial infarction or heart failure—and our ﬁ nding 
of no association suggests that the higher risk of cardiac 
arrest with type 2 diabetes is mediated by atherosclerotic 
coronary disease.
Sex diﬀ erences in the eﬀ ect of diabetes on coronary 
heart disease have been the subject of several reviews 
and meta-analyses.24 Although the absolute risk for 
coronary heart disease morbidity and mortality is lower 
in women than in men, the relative risk associated with 
diabetes has generally been reported to be higher in 
women,7,25,26 potentially due to their adverse risk-factor 
proﬁ le.26 The most recent meta-analysis of prospective 
studies focusing on diabetes reported relative risks for 
incident coronary heart disease of 2·63 for women and 
1·85 for men with diabetes.7 Sex diﬀ erences in the 
association of type 2 diabetes with outcomes other than 
coronary heart disease have less often been reported, 
with conﬂ icting results for stroke.27,28 In participants 
younger than 60 years, we noted weak evidence of a 
slightly stronger association of type 2 diabetes with 
myocardial infarction in women than in men—which is 
consistent with previous reports—but no other sex 
diﬀ erences in associations between type 2 diabetes and 
cardiovascular outcomes.24
Our ﬁ nding that HbA1c concentrations were associated 
with the risk of many cardiovascular diseases strengthens 
the case for the causal relevance of blood glucose in 
type 2 diabetes-related cardiovascular disease. These 
associations were particularly strong for peripheral 
arterial disease, and persisted even in participants with 
an HbA1c concentration of less than 48 mmol/mol 
(6·5%), suggesting that risk is not controlled in this 
group. Individuals in whom HbA1c had not been 
measured were at higher risk, consistent with 
measurement being a marker of overall quality of care.
Our results support the use of clinically collected real-
world cohorts from electronic health records to provide 
such evidence of absolute and relative risks of diﬀ erent 
disease outcomes in people with type 2 diabetes, and to 
complement ﬁ ndings from conventional investigator-led 
cohort studies,4 which typically are smaller, not 
contemporary, and have less external validity.
Our results will help to inform drug development and 
the design of trials in type 2 diabetes. Trials3 have often 
included acute myocardial infarction and acute stroke as 
their primary event endpoints, because of a previous 
perception that these outcomes were the main disease 
burdens in type 2 diabetes, or that they are easier to 
ascertain and validate than chronic disease endpoints. 
We propose that chronic disease endpoints such as heart 
failure, peripheral arterial disease, and stable angina are 
important to consider in the choice of primary endpoint 
because they are common, have a high morbidity burden, 
and might have diﬀ erent treatment eﬀ ects from 
myocardial infarction or stroke.
Although a strength of this study is the ability to 
diﬀ erentiate a wide range of cardiovascular diseases in a 
validated electronic health record linkage, the accuracy 
and amount of phenotypic detail recorded in such 
databases is limited. Residual confounding due to diet, 
physical activity, stress, and environmental factors 
might be a potential source of bias. Although coding for 
type 2 diabetes is prone to error in clinical practice,29 
coding error is unlikely to be an important source of 
bias in our study because our analyses, based on the 
diagnostic11 marker of HbA1c, were consistent with the 
overall results. The age-speciﬁ c prevalences of type 2 
diabetes we estimated are similar to those from a 
national survey done at a similar time to our study.30 
Error might occur in the recording of the cardiovascular 
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